Bayer has signed an agreement with CureVac N.V., a biopharma company that manufactures medication based on messenger ribonucleic acid (mRNA). Per the deal, Bayer will help with development, supply and territory operations of CureVac’s Covid-19 vaccine candidate, CVnCoV.
As of Dec. 14, the vaccine has been in Phase IIb/III.
Bayer will offer its perspective in areas including clinical operations, regulatory affairs, pharmacovigilance, medical information and supply chain performance.
CureVac will be the marketing authorization (MA) holder for the product, while Bayer will support CureVac with country operations in the EU and other markets. Bayer also holds options to become MA holder in markets outside of Europe. The companies plan to work together on enabling CureVac to supply hundreds of millions of CVnCoV doses internationally, if approvals are granted.
In November 2020, CureVac announced that it would expand up its European manufacturing network, working with Wacker and Fareva, among others.